Top Markets
Coin of the day
DelMar Pharmaceuticals, Inc. DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc.

DMPWW
Rank in Stocks #42376
Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc.... Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.
Share Price
$0.005
Last synced: 2024-06-20
Market Cap
$1.74K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade DelMar Pharmaceuticals, Inc. (DMPWW)

Category

Stock price history for DelMar Pharmaceuticals, Inc. (DMPWW)
Highest end of day price: $0.00 on 2024-06-01

Lowest end of day price: $0.05 on 2022-01-01
Stock price history of DelMar Pharmaceuticals, Inc. from 2022 to 2026
Annual Stock Price Performance
Year Performance
2024 79.76%
2023 -86.88%
2022 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$527.87 33.33%
US
$873.57 35.10%
NL
$736.38 7.69%
CH
$263.09 18.09%
BE
$1.08K -6.86%
KR